vs
BLUE RIDGE BANKSHARES, INC.（BRBS）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
RECURSION PHARMACEUTICALS, INC.的季度营收约是BLUE RIDGE BANKSHARES, INC.的1.7倍（$35.5M vs $20.8M），BLUE RIDGE BANKSHARES, INC.净利率更高（20.4% vs -304.2%，领先324.6%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -5.2%），BLUE RIDGE BANKSHARES, INC.自由现金流更多（$11.9M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -14.0%）
Blue Ridge Bankshares Inc.是一家总部位于美国的金融控股公司，通过旗下银行子公司开展业务，提供零售及商业银行服务，包含存款、各类贷款、财富管理等解决方案，核心服务区域覆盖弗吉尼亚州和北卡罗来纳州，客群涵盖个人消费者及中小微企业。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
BRBS vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.8M | $35.5M |
| 净利润 | $4.2M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 25.9% | -304.8% |
| 净利率 | 20.4% | -304.2% |
| 营收同比 | -5.2% | 681.7% |
| 净利润同比 | 311.9% | 39.6% |
| 每股收益（稀释后） | $0.05 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $20.8M | $35.5M | ||
| Q3 25 | $25.7M | $5.2M | ||
| Q2 25 | $23.1M | $19.2M | ||
| Q1 25 | $22.1M | $14.7M | ||
| Q4 24 | $21.9M | $4.5M | ||
| Q3 24 | $21.8M | $26.1M | ||
| Q2 24 | $20.4M | $14.4M | ||
| Q1 24 | $28.1M | $13.8M |
| Q4 25 | $4.2M | $-108.1M | ||
| Q3 25 | $5.6M | $-162.3M | ||
| Q2 25 | $1.3M | $-171.9M | ||
| Q1 25 | $-434.0K | $-202.5M | ||
| Q4 24 | $-2.0M | $-178.9M | ||
| Q3 24 | $946.0K | $-95.8M | ||
| Q2 24 | $-11.4M | $-97.5M | ||
| Q1 24 | $-2.9M | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
| Q4 25 | 25.9% | -304.8% | ||
| Q3 25 | 29.1% | -3327.6% | ||
| Q2 25 | 7.7% | -916.8% | ||
| Q1 25 | -4.0% | -1297.9% | ||
| Q4 24 | -14.1% | -4042.4% | ||
| Q3 24 | 7.1% | -377.1% | ||
| Q2 24 | -59.2% | -697.4% | ||
| Q1 24 | -11.7% | -698.4% |
| Q4 25 | 20.4% | -304.2% | ||
| Q3 25 | 21.8% | -3135.3% | ||
| Q2 25 | 5.6% | -894.2% | ||
| Q1 25 | -2.0% | -1373.3% | ||
| Q4 24 | -10.5% | -3935.5% | ||
| Q3 24 | 4.3% | -367.5% | ||
| Q2 24 | -56.2% | -676.6% | ||
| Q1 24 | -10.3% | -662.4% |
| Q4 25 | $0.05 | $-0.17 | ||
| Q3 25 | $0.06 | $-0.36 | ||
| Q2 25 | $0.01 | $-0.41 | ||
| Q1 25 | $-0.01 | $-0.50 | ||
| Q4 24 | $0.30 | $-0.56 | ||
| Q3 24 | $0.01 | $-0.34 | ||
| Q2 24 | $-0.47 | $-0.40 | ||
| Q1 24 | $-0.15 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $323.7M | $1.1B |
| 总资产 | $2.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M | ||
| Q1 24 | — | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M | ||
| Q1 24 | — | — |
| Q4 25 | $323.7M | $1.1B | ||
| Q3 25 | $355.5M | $1.0B | ||
| Q2 25 | $344.3M | $919.1M | ||
| Q1 25 | $338.3M | $933.9M | ||
| Q4 24 | $327.8M | $1.0B | ||
| Q3 24 | $336.3M | $524.6M | ||
| Q2 24 | $325.6M | $584.4M | ||
| Q1 24 | $180.9M | $401.2M |
| Q4 25 | $2.4B | $1.5B | ||
| Q3 25 | $2.5B | $1.4B | ||
| Q2 25 | $2.6B | $1.3B | ||
| Q1 25 | $2.7B | $1.3B | ||
| Q4 24 | $2.7B | $1.4B | ||
| Q3 24 | $2.9B | $726.5M | ||
| Q2 24 | $2.9B | $775.9M | ||
| Q1 24 | $3.1B | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.6M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $11.9M | $-47.3M |
| 自由现金流率自由现金流/营收 | 57.4% | -133.1% |
| 资本支出强度资本支出/营收 | 8.1% | 3.5% |
| 现金转化率经营现金流/净利润 | 3.21× | — |
| 过去12个月自由现金流最近4个季度 | $24.6M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $13.6M | $-46.1M | ||
| Q3 25 | $6.4M | $-117.4M | ||
| Q2 25 | $10.7M | $-76.4M | ||
| Q1 25 | $-3.6M | $-132.0M | ||
| Q4 24 | $-6.3M | $-115.4M | ||
| Q3 24 | $24.1M | $-59.2M | ||
| Q2 24 | $-4.8M | $-82.2M | ||
| Q1 24 | $-7.5M | $-102.3M |
| Q4 25 | $11.9M | $-47.3M | ||
| Q3 25 | $5.7M | $-117.6M | ||
| Q2 25 | $10.5M | $-79.6M | ||
| Q1 25 | $-3.6M | $-133.8M | ||
| Q4 24 | $-6.9M | $-116.7M | ||
| Q3 24 | $23.9M | $-63.8M | ||
| Q2 24 | $-5.0M | $-83.4M | ||
| Q1 24 | $-7.6M | $-109.0M |
| Q4 25 | 57.4% | -133.1% | ||
| Q3 25 | 22.3% | -2272.5% | ||
| Q2 25 | 45.6% | -413.9% | ||
| Q1 25 | -16.4% | -907.4% | ||
| Q4 24 | -31.4% | -2567.7% | ||
| Q3 24 | 109.6% | -244.6% | ||
| Q2 24 | -24.4% | -578.5% | ||
| Q1 24 | -26.9% | -789.9% |
| Q4 25 | 8.1% | 3.5% | ||
| Q3 25 | 2.7% | 4.7% | ||
| Q2 25 | 0.6% | 16.4% | ||
| Q1 25 | 0.1% | 12.4% | ||
| Q4 24 | 2.7% | 28.6% | ||
| Q3 24 | 1.1% | 17.5% | ||
| Q2 24 | 0.8% | 8.2% | ||
| Q1 24 | 0.2% | 48.2% |
| Q4 25 | 3.21× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 8.22× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.51× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
